SANTA
CLARA, Calif., Feb. 18,
2025 /PRNewswire/ -- Semler Scientific, Inc.
(Nasdaq: SMLR), a pioneer in developing and marketing technology
products and services to healthcare providers to combat chronic
diseases, today reported financial results for the fourth quarter
and year ended December 31, 2024.
"We are again pleased to report strong performance from our
healthcare business with income from operations of $20.9 million for the full year 2024," said
Doug Murphy-Chutorian, MD, chief
executive officer of Semler Scientific. "While we continue to
support innovation and growth in our healthcare business, our main
use of cash is to acquire and hold bitcoin."
"2024 was a transformative year for Semler Scientific as we
embraced a bitcoin treasury strategy to maximize
stockholder value," said Eric
Semler, chairman of Semler Scientific. "Through a
disciplined and accretive approach, we have acquired 3,192
bitcoins, which are now valued at approximately $300 million. Since launching this strategy in
May 2024, our market capitalization
has increased more than 200%. We have unwavering confidence in
bitcoin's long-term potential and view it as digital
gold. With this conviction, we remain committed to significantly
expanding our bitcoin holdings."
BITCOIN TREASURY HIGHLIGHTS AND OTHER RECENT
DEVELOPMENTS
- "BTC Yield" KPI: For the year ended December 31, 2024, Semler Scientific's BTC Yield
was 107%. BTC Yield is a key performance indicator (KPI) that
Semler Scientific uses to help assess the performance of its
strategy of acquiring bitcoin in a manner it believes
is accretive to stockholders. See "Important Information about BTC
Yield KPI" in this press release for the definition of BTC Yield
and how it is calculated.
- Digital Assets: As of December
31, 2024, Semler Scientific held 2,298 bitcoins with a fair
value of $214.6 million, which
reflects a cumulative increase in fair value of $24.9 million. During the year ended December 31, 2024, Semler Scientific purchased
2,298 bitcoins for an aggregate cost of $189.7 million. Subsequently through February 14, 2025, Semler Scientific purchased an
additional 894 bitcoins for an aggregate cost of $90.7 million. Semler Scientific's total holdings
as of February 14, 2025 are 3,192
bitcoins for an aggregate purchase amount of $280.4 million from operating cashflow,
monetization of a portion of its minority interest in Monarch
Medical Technologies, LLC, as well as proceeds from its ATM and
senior convertible notes offerings. All purchase amounts include
fees and expenses.
- At-the-Market Equity Offering Program: Semler Scientific
entered into a Controlled Equity Offeringsm Sales
Agreement (the Sales Agreement) with Cantor Fitzgerald & Co.,
pursuant to which it may issue and sell from time to time up to
$150.0 million of its common stock in
an at-the-market (ATM) offering. As of December 31, 2024, Semler Scientific had sold an
aggregate of 2,197,988 shares under the Sales Agreement for
aggregate net proceeds (less sales commissions) of approximately
$119.6 million.
- Issuance of 4.25% Convertible Notes due 2030: In
January 2025, Semler Scientific
issued $100.0 million aggregate
principal amount of 4.25% Convertible Senior Notes due 2030 (the
Notes), including the exercise in full of the initial purchasers'
option to purchase up to an additional $15.0
million principal amount of the Notes. The Notes have an
initial conversion price of approximately $76.44 per share of common stock. At the same
time, Semler Scientific entered into capped call transactions in
connection with the notes with an initial cap price of
approximately $107.01 per share of
common stock.
FINANCIAL RESULTS
For the year ended December 31,
2024, compared to the corresponding period of 2023, Semler
Scientific reported:
- Revenues of $56.3 million, a
decrease of $11.9 million, or 17%,
compared to $68.2 million.
- Cost of revenues of $4.8 million,
a decrease of $2.2 million or 32%
compared to $7.0 million. Cost of
revenues for the full year ended December
31, 2023 includes a $2.5
million write-off of prepaid software licenses for Insulin
Insights.
- Total operating expenses, which includes cost of revenues, of
$35.4 million, a decrease of
$10.5 million, or 23%, compared to
$45.9 million.
- Income from operations of $20.9
million, a decrease of $1.4
million, or 6%, compared to $22.3
million.
- Pre-tax income of $47.9 million
(which includes an unrealized gain from the change in fair value of
Semler Scientific's bitcoin holdings of $24.9 million), an increase of $23.8 million, or 99%, compared to $24.1 million.
- Income tax expense of $7.0
million, or an effective tax rate of 15%, compared to
$3.5 million, or an effective tax
rate of 15%.
- Net income of $40.9 million, or
$5.66 per basic share and
$5.13 per diluted share, an increase
of $20.3 million, or 99%, compared to
$20.6 million, or $3.06 per basic share and $2.63 per diluted share.
Semler Scientific's two largest customers (including their
affiliates) comprised 43% and 28% of full year revenues in 2024,
respectively, and 36% and 35% of full year revenues in 2023,
respectively.
For the fourth quarter ended December 31,
2024, compared to the corresponding period of 2023, Semler
Scientific reported:
- Revenues of $12.4 million, a
decrease of $2.7 million, or 18%,
compared to $15.1 million.
- Cost of revenues of $1.1 million,
a decrease of $2.3 million, or 67%,
compared to $3.4 million. Cost of
revenues for the fourth quarter ended December 31, 2023 includes a $2.5 million write-off of prepaid software
licenses for Insulin Insights.
- Total operating expenses, which include cost of revenues, of
$8.9 million, a decrease of
$3.6 million, or 29%, compared to
$12.5 million.
- Income from operations of $3.5
million, an increase of $1.0
million, or 40%, compared to $2.5
million.
- Pre-tax income of $32.6 million
(which includes an unrealized gain from the change in fair value of
Semler Scientific's bitcoin holdings of $28.8 million), an increase of $29.8 million, or 1,058%, compared to
$2.8 million.
- Income tax expense of $3.4
million, or an effective tax rate of 10%, compared to income
tax benefit of $1.4 million, or an
effective tax benefit of 50%.
- Net income of $29.2 million or
$3.64 per basic share and
$3.41 per diluted share, an increase
of $25.0 million, or 592%, compared
to net income of $4.2 million, or
$0.62 per basic share and
$0.55 per diluted share.
Semler Scientific's two largest customers (including their
affiliates) comprised 39% and 31% of fourth quarter revenues in
2024, respectively, and its three largest customers comprised
37%, 32% and 11% of fourth quarter 2023 revenues, respectively.
Notice of Conference Call
Semler Scientific will host a conference call today at
4:30 p.m. ET. The call will address
results of the fourth quarter and year ended December 31, 2024, as well as provide a business
update on Semler Scientific's strategies for the near-term
future. Questions can be submitted prior to the start of the call
to ir@semlerscientific.com.
Participants are encouraged to pre-register for the conference
call using the following link:
https://dpregister.com/sreg/10196221/fe5ab5166e. Callers
who pre-register will be given a conference passcode and unique PIN
to gain immediate access to the call and bypass the live operator.
Participants may pre-register at any time, including up to and
after the call start time. Those without internet access or who are
unable to pre-register may dial in by calling:
Domestic callers: (833) 816–1161
International callers: (412) 317–0717
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
|
Semler
Scientific, Inc.
Statements of
Income
(In thousands of
U.S. Dollars, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months
ended December 31,
|
|
For the year ended
December 31,
|
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
|
|
Unaudited
|
|
|
Unaudited
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
12,413
|
|
$
|
15,056
|
|
$
|
56,294
|
|
$
|
68,184
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
revenues
|
|
|
1,102
|
|
|
3,384
|
|
|
4,759
|
|
|
6,984
|
|
Engineering and product
development
|
|
|
1,028
|
|
|
1,207
|
|
|
4,792
|
|
|
5,773
|
|
Sales and
marketing
|
|
|
2,971
|
|
|
4,546
|
|
|
13,078
|
|
|
18,147
|
|
General and
administrative
|
|
|
3,770
|
|
|
3,262
|
|
|
12,732
|
|
|
14,290
|
|
Strategic
streamlining
|
|
|
—
|
|
|
135
|
|
|
—
|
|
|
734
|
|
Total operating
expenses
|
|
|
8,871
|
|
|
12,534
|
|
|
35,361
|
|
|
45,928
|
|
Income from
operations
|
|
|
3,542
|
|
|
2,522
|
|
|
20,933
|
|
|
22,256
|
|
Interest and dividend
income, net
|
|
|
179
|
|
|
699
|
|
|
1,877
|
|
|
2,471
|
|
Impairment of
investments
|
|
|
—
|
|
|
(337)
|
|
|
—
|
|
|
(337)
|
|
Change in fair value of
notes held for investment
|
|
|
—
|
|
|
(90)
|
|
|
128
|
|
|
(307)
|
|
Change in fair value of
digital assets
|
|
|
28,850
|
|
|
—
|
|
|
24,933
|
|
|
—
|
|
Other income
|
|
|
5
|
|
|
20
|
|
|
13
|
|
|
17
|
|
Other income,
net
|
|
|
29,034
|
|
|
292
|
|
|
26,951
|
|
|
1,844
|
|
Pre-tax
income
|
|
|
32,576
|
|
|
2,814
|
|
|
47,884
|
|
|
24,100
|
|
Income tax
provision
|
|
|
3,370
|
|
|
(1,407)
|
|
|
6,985
|
|
|
3,517
|
|
Net income
|
|
$
|
29,206
|
|
$
|
4,221
|
|
$
|
40,899
|
|
$
|
20,583
|
|
Net income per share,
basic
|
|
$
|
3.64
|
|
$
|
0.62
|
|
$
|
5.66
|
|
$
|
3.06
|
|
Weighted average number
of shares used in computing basic net income per share
|
|
|
8,033,757
|
|
|
6,804,998
|
|
|
7,228,961
|
|
|
6,732,806
|
|
Net income per share,
diluted
|
|
$
|
3.41
|
|
$
|
0.55
|
|
$
|
5.13
|
|
$
|
2.63
|
|
Weighted average number
of shares used in computing diluted net income per share
|
|
|
8,566,619
|
|
|
7,734,263
|
|
|
7,980,118
|
|
|
7,819,159
|
|
Semler
Scientific, Inc.
Balance
Sheets
(In thousands of
U.S. Dollars, except share and per share data)
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
December 31,
|
|
|
2024
|
|
2023
|
|
Assets
|
|
|
|
|
|
|
|
Current
Assets:
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
8,819
|
|
$
|
57,200
|
|
Restricted
cash
|
|
|
133
|
|
|
132
|
|
Trade accounts
receivable, net of allowance for credit losses of $199 and $287,
respectively
|
|
|
4,378
|
|
|
6,125
|
|
Short-term notes held
for investment
|
|
|
6,100
|
|
|
—
|
|
Inventory,
net
|
|
|
358
|
|
|
445
|
|
Prepaid expenses and
other current assets
|
|
|
2,900
|
|
|
2,042
|
|
Total current
assets
|
|
|
22,688
|
|
|
65,944
|
|
Assets for lease,
net
|
|
|
1,423
|
|
|
2,285
|
|
Property and equipment,
net
|
|
|
487
|
|
|
720
|
|
Long-term
investments
|
|
|
512
|
|
|
512
|
|
Notes held for
investment
|
|
|
—
|
|
|
5,372
|
|
Intangible digital
assets
|
|
|
214,633
|
|
|
—
|
|
Other non-current
assets
|
|
|
85
|
|
|
270
|
|
Deferred tax
assets
|
|
|
—
|
|
|
2,962
|
|
Total
assets
|
|
$
|
239,828
|
|
$
|
78,065
|
|
|
|
|
|
|
|
|
Liabilities and
Stockholders' Equity
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
140
|
|
$
|
402
|
|
Accrued
expenses
|
|
|
5,173
|
|
|
4,502
|
|
Deferred
revenue
|
|
|
774
|
|
|
1,120
|
|
Other short-term
liabilities
|
|
|
226
|
|
|
176
|
|
Total current
liabilities
|
|
|
6,313
|
|
|
6,200
|
|
|
|
|
|
|
|
|
Long-term
liabilities:
|
|
|
|
|
|
|
|
Deferred tax
liability
|
|
|
2,765
|
|
|
—
|
|
Other long-term
liabilities
|
|
|
—
|
|
|
70
|
|
Total long-term
liabilities
|
|
|
2,765
|
|
|
70
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
|
Common stock, $0.001
par value; 50,000,000 shares authorized; 9,770,908 and 7,099,441
shares
issued, and 9,556,486
and 6,885,019 shares outstanding (treasury shares of 214,422 and
214,422),
respectively
|
|
|
9
|
|
|
7
|
|
Additional paid-in
capital
|
|
|
130,039
|
|
|
11,985
|
|
Retained
earnings
|
|
|
100,702
|
|
|
59,803
|
|
Total stockholders'
equity
|
|
|
230,750
|
|
|
71,795
|
|
|
|
|
|
|
|
|
Total liabilities and
stockholders' equity
|
|
$
|
239,828
|
|
$
|
78,065
|
|
Semler
Scientific, Inc.
Statements of Cash
Flows
(In thousands of
U.S. Dollars)
|
|
|
|
|
|
|
|
|
|
For the year ended
December 31,
|
|
|
2024
|
|
2023
|
|
CASH FLOWS FROM
OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
Net income
|
|
$
|
40,899
|
|
$
|
20,583
|
|
|
|
|
|
|
|
|
Reconciliation of Net
Income to Net Cash Provided by Operating Activities:
|
|
|
|
|
|
|
|
Depreciation
|
|
|
579
|
|
|
599
|
|
Deferred tax
expense (income)
|
|
|
5,727
|
|
|
(664)
|
|
Loss on disposal
of assets for lease
|
|
|
298
|
|
|
369
|
|
Write off of
prepaid software licenses
|
|
|
—
|
|
|
2,476
|
|
Gain on
short-term investments
|
|
|
—
|
|
|
(151)
|
|
Allowance for
credit losses
|
|
|
(88)
|
|
|
268
|
|
Change in fair
value of notes held for investment
|
|
|
(128)
|
|
|
307
|
|
Change in fair
value of digital assets
|
|
|
(24,933)
|
|
|
—
|
|
Stock-based
compensation
|
|
|
862
|
|
|
944
|
|
Impairment of
long-term investments
|
|
|
—
|
|
|
337
|
|
Changes in Operating
Assets and Liabilities:
|
|
|
|
|
|
|
|
Trade accounts
receivable
|
|
|
1,844
|
|
|
(2,508)
|
|
Inventory
|
|
|
88
|
|
|
24
|
|
Prepaid expenses
and other current assets
|
|
|
(865)
|
|
|
(603)
|
|
Other
non-current assets
|
|
|
85
|
|
|
96
|
|
Accounts
payable
|
|
|
(262)
|
|
|
(433)
|
|
Accrued
expenses
|
|
|
671
|
|
|
(246)
|
|
Other current
and non-current liabilities
|
|
|
(367)
|
|
|
(68)
|
|
Net Cash Provided
by Operating Activities
|
|
|
24,410
|
|
|
21,330
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
Additions to property
and equipment
|
|
|
(51)
|
|
|
(345)
|
|
Purchase of notes held
for investment
|
|
|
(500)
|
|
|
(1,000)
|
|
Purchase of digital
assets
|
|
|
(189,700)
|
|
|
—
|
|
Proceeds from
maturities of short-term investments
|
|
|
—
|
|
|
78,093
|
|
Purchase of short-term
investments
|
|
|
—
|
|
|
(57,869)
|
|
Proceeds from sale
(purchase) of assets for lease
|
|
|
269
|
|
|
(483)
|
|
Net Cash (Used in)
Provided by Investing Activities
|
|
|
(189,982)
|
|
|
18,396
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
Proceeds from issuance
of common stock
|
|
|
119,602
|
|
|
—
|
|
Taxes paid related to
net settlement of equity awards
|
|
|
(874)
|
|
|
(3,510)
|
|
Common stock warrants
acquired
|
|
|
—
|
|
|
(1,949)
|
|
Stock issuance
expenses
|
|
|
(3,000)
|
|
|
—
|
|
Proceeds from exercise
of stock options
|
|
|
1,464
|
|
|
51
|
|
Net Cash Provided
by (Used in) Financing Activities
|
|
|
117,192
|
|
|
(5,408)
|
|
NET (DECREASE)
INCREASE IN CASH AND CASH EQUIVALENTS
|
|
|
(48,380)
|
|
|
34,318
|
|
CASH, CASH
EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF
PERIOD
|
|
|
57,332
|
|
|
23,014
|
|
CASH, CASH
EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD
|
|
$
|
8,952
|
|
$
|
57,332
|
|
Supplemental Disclosure
of Cash Flow Information:
|
|
|
|
|
|
|
|
Cash paid for
taxes
|
|
$
|
2,260
|
|
$
|
4,060
|
|
Semler
Scientific, Inc.
Digital Assets-
Additional Information
Rollforward of
bitcoin
holdings
(in thousands of us
dollars, except bitcoin
held and price per bitcoin)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Source
of
|
|
|
|
|
|
|
|
|
|
|
|
Approximate
|
|
Capital
|
|
|
|
|
|
|
|
|
|
|
|
|
Average
|
|
Used
to
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
|
|
Purchase
|
|
Digital
Assets
|
|
Change
in
|
|
Digital
Assets
|
Approximate
|
|
Price
Per
|
|
Bitcoin
|
|
at
Cost
|
|
Fair
Value
|
|
at Fair
Value
|
Bitcoin Held
|
|
Bitcoin (in $)
|
|
Balance as of December
31, 2023
|
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
—
|
|
$
|
—
|
|
Digital assets
purchased
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
Balance as of March 31,
2024
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
Digital assets
purchased
|
(a)
|
|
|
60,000
|
|
|
—
|
|
|
60,000
|
|
877
|
|
|
68,436
|
|
Change in fair value of
the digital assets
|
|
|
|
—
|
|
|
(5,055)
|
|
|
(5,055)
|
|
—
|
|
|
—
|
|
Balance as of June 30,
2024
|
|
|
$
|
60,000
|
|
$
|
(5,055)
|
|
$
|
54,945
|
|
877
|
|
$
|
68,436
|
|
Digital assets
purchased
|
(b)
|
|
|
8,400
|
|
|
—
|
|
|
8,400
|
|
141
|
|
|
59,372
|
|
Change in fair value of
the digital assets
|
|
|
|
—
|
|
|
1,137
|
|
|
1,137
|
|
—
|
|
|
—
|
|
Balance as of September
30, 2024
|
|
|
$
|
68,400
|
|
$
|
(3,918)
|
|
$
|
64,482
|
|
1,018
|
|
$
|
59,372
|
|
Digital assets
purchased
|
(b)
|
|
|
121,300
|
|
|
—
|
|
|
121,300
|
|
1,280
|
|
|
94,755
|
|
Change in fair value of
the digital assets
|
|
|
|
—
|
|
|
28,851
|
|
|
28,851
|
|
—
|
|
|
—
|
|
Balance as of December
31, 2024
|
|
|
$
|
189,700
|
|
$
|
24,933
|
|
$
|
214,633
|
|
2,298
|
|
$
|
82,538
|
|
|
|
(a)
|
Cash from
operations
|
|
(b)
|
Cash from operations
and proceeds from ATM offering.
|
Important Information about BTC Yield Key Performance
Indicator (KPI)
Semler Scientific uses BTC Yield as a KPI to help assess the
performance of its strategy of acquiring bitcoin in a
manner Semler Scientific believes is accretive to stockholders.
Semler Scientific believes this KPI can be used to supplement an
investor's understanding of Semler Scientific's decision to fund
the purchase of bitcoin by issuing additional shares
of its common stock. When Semler Scientific uses this KPI,
management also takes into account the various limitations of this
metric.
BTC Yield is a KPI that represents the percentage change
period-to-period of the ratio between Semler Scientific's
bitcoin holdings and its Assumed Diluted Shares
Outstanding. Assumed Diluted Shares Outstanding refers to the
aggregate of Semler Scientific's actual shares of common stock
outstanding as of the end of each period plus all additional shares
that would result from the assumed exercise of all outstanding
stock option awards. Assumed Diluted Shares Outstanding is not
calculated using the treasury method and does not take into account
any vesting conditions or the exercise price of any stock option
awards.
Additionally, this KPI is not, and should not be understood as,
an operating performance measure or a financial or liquidity
measure. In particular, BTC Yield is not equivalent to a "yield" in
the traditional financial context. It is not a measure of the
return on investment Semler Scientific's stockholders may have
achieved historically or can achieve in the future by purchasing
stock of Semler Scientific, or a measure of income generated by
Semler Scientific's operations or its bitcoin
holdings, return on investment on its bitcoin
holdings, or any other similar financial measure of the performance
of its business or assets.
The trading price of Semler Scientific's common stock is
informed by numerous factors in addition to the amount of bitcoins
Semler Scientific holds and number of actual or potential shares of
its stock outstanding. As a result, the market value of Semler
Scientific's shares may trade at a discount or a premium relative
to the market value of the bitcoin Semler Scientific
holds. BTC Yield is not indicative nor predictive of the trading
price of Semler Scientific's shares of common stock. As noted
above, this KPI is narrow in its purpose and is used by management
to assist in assessing whether Semler Scientific is using equity
capital in a manner accretive to stockholders solely as it pertains
to its bitcoin holdings.
In calculating this KPI, Semler Scientific does not take into
account the source of capital used for the acquisition of its
bitcoin. Semler Scientific notes in particular, it has
acquired bitcoin using cash flow from operations, as
well as proceeds from the sale of shares in the ATM offering and
sale of the notes. Accordingly, this metric might overstate or
understate the accretive nature of Semler Scientific's use of
equity capital to buy bitcoin because not all
bitcoin may be acquired using proceeds of equity and
debt offerings and not all issuances of equity may involve the
acquisition of bitcoin.
Semler Scientific's ability to achieve positive BTC Yield may
depend on a variety of factors, including its ability to generate
cash from operations in excess of its fixed charges and other
expenses, as well as factors outside of its control, such as the
availability of debt and equity financing on favorable terms. Past
performance is not indicative of future results.
Semler Scientific has historically not paid dividends on its
shares of common stock, and by presenting this KPI, Semler
Scientific makes no suggestion that it intends to do so in the
future. Ownership of common stock does not represent an ownership
interest in the bitcoin Semler Scientific holds.
Investors should rely on the financial statements and other
disclosures contained in Semler Scientific's SEC filings. This KPI
is merely a supplement, not a substitute. It should be used only by
sophisticated investors who understand its limited purpose and many
limitations.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a pioneer in developing and marketing
technology products and services to healthcare providers to combat
chronic diseases. Its flagship product, QuantaFlo®,
which is patented and cleared by the U.S. Food and Drug
Administration (FDA), is a rapid point-of-care test that measures
arterial blood flow in the extremities. The QuantaFlo test aids in
the diagnosis of cardiovascular diseases, such as peripheral
arterial disease (PAD), and Semler Scientific is seeking a new
510(k) clearance for expanded-indications. QuantaFlo is used by
healthcare providers to evaluate their patient's risk of mortality
and major adverse cardiovascular events (MACE). Semler Scientific
also invests in bitcoin and has adopted
Bitcoin as its primary treasury asset. Additional
information about Semler Scientific can be found at
www.semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking" statements. Such
statements can be identified by, among other things, the use of
forward-looking language such as the words "believe," "goal,"
"may," "will," "intend," "expect," "anticipate," "estimate,"
"project," "would," "could" or words with similar meaning or the
negatives of these terms or by the discussion of strategy or
intentions. The forward-looking statements in this release include
express or implied statements regarding acquiring and holding
bitcoin; as well as innovation and growth in its
healthcare business; and sales of securities under the Sales
Agreement and other financings to support additional
bitcoin purchases including the notes and; seeking a
new 510(k) clearance for QuantaFlo with expanded indications; among
others. Such forward-looking statements are subject to a number of
risks and uncertainties that could cause Semler Scientific's actual
results to differ materially from those discussed here, such as
risks inherent with investing in bitcoin, including
bitcoin's volatility; risk of implementing a new
bitcoin treasury strategy; risk that insurance plans
and other customers will not continue to license its cardiovascular
testing products; risk of changes in the reimbursement landscape
for its customers including related to the Centers for Medicare and
Medicaid Services (CMS) rate announcement; risk of obtaining a new
510(k) clearance for expanded indications; along with those other
risk factors detailed in Semler Scientific's filings with the
Securities and Exchange Commission. These forward-looking
statements involve assumptions, estimates, and uncertainties that
reflect current internal projections, expectations or beliefs.
There can be no assurance that such statements will prove to be
accurate, and actual results and future events could differ
materially from those anticipated in such statements. All
forward-looking statements contained in this press release are
qualified in their entirety by these cautionary statements and the
risk factors described above. Furthermore, all such statements are
made as of the date of this press release and Semler Scientific
assumes no obligation to update or revise these statements unless
otherwise required by law.
No Offer or Solicitation
This press release does not and shall not constitute an offer to
sell or a solicitation of an offer to buy any securities of Semler
Scientific, Inc., nor shall there be any offer, solicitation or
sale of such securities, in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
INVESTOR CONTACT:
Renae Cormier
Chief Financial Officer
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-reports-fourth-quarter-and-full-year-2024-financial-results-with-a-btc-yield-of-107-since-july-1--2024-now-holds-3-192-btc-302379320.html
SOURCE Semler Scientific, Inc.